2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-12-14

AUTHORS

Hao Liu, Chen Chen Jiang, Christopher J Lavis, Amanda Croft, Li Dong, Hsin-Yi Tseng, Fan Yang, Kwang Hong Tay, Peter Hersey, Xu Dong Zhang

ABSTRACT

BackgroundPast studies have shown that sensitivity of melanoma cells to TRAIL-induced apoptosis is largely correlated with the expression levels of TRAIL death receptors on the cell surface. However, fresh melanoma isolates and melanoma tissue sections express generally low levels of death receptors for TRAIL. The clinical potential of TRAIL in the treatment of melanoma may therefore be limited unless given with agents that increase the cell surface expression of TRAIL death receptors. 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analogue that inhibits glycolysis and glycosylation and blocks cell growth. It has been in clinical evaluation for its potential use as an anticancer agent. In this study, we have examined whether 2-DG and TRAIL interact to enhance their cytotoxicity towards melanoma cells.Results2-DG did not kill melanoma cells, but enhanced TRAIL-induced apoptosis in cultured melanoma cells and fresh melanoma isolates. This was associated with increased activation of the caspase cascade and mitochondrial apoptotic pathway, and was blocked by inhibition of TRAIL-R2, and to a lesser extent, inhibition of TRAIL-R1. Treatment with 2-DG up-regulated TRAIL death receptors, in particular, TRAIL-R2, on the melanoma cell surface. Up-regulation of TRAIL-R2 was due to increased transcription that was not dependent on the transcription factors, p53 and CHOP. Instead, the IRE1α and ATF6 pathways of the unfolded protein response that were activated by 2-DG appeared to be involved. Moreover, XBP-1, which is known to be transcriptionally regulated by ATF6 and functionally activated by IRE1α, was found to play an important role in 2-DG-mediated transcriptional up-regulation of TRAIL-R2 in melanoma cells.ConclusionThese results indicate that 2-DG sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-2 via the ATF6/IRE1α/XBP-1 axis of the unfolded protein response. They suggest that 2-DG is a promising agent to increase the therapeutic response to TRAIL in melanoma. More... »

PAGES

122

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1476-4598-8-122

DOI

http://dx.doi.org/10.1186/1476-4598-8-122

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037487578

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20003459


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA-Binding Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxyglucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycosylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, TNF-Related Apoptosis-Inducing Ligand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regulatory Factor X Transcription Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TNF-Related Apoptosis-Inducing Ligand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Up-Regulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "X-Box Binding Protein 1", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, PR China", 
          "id": "http://www.grid.ac/institutes/grid.252957.e", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
            "Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, PR China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Hao", 
        "id": "sg:person.01212142420.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212142420.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jiang", 
        "givenName": "Chen Chen", 
        "id": "sg:person.0617201523.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617201523.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lavis", 
        "givenName": "Christopher J", 
        "id": "sg:person.01007554442.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007554442.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Croft", 
        "givenName": "Amanda", 
        "id": "sg:person.01215144734.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215144734.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dong", 
        "givenName": "Li", 
        "id": "sg:person.01136142016.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136142016.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tseng", 
        "givenName": "Hsin-Yi", 
        "id": "sg:person.01032164214.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032164214.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Fan", 
        "id": "sg:person.0755651204.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755651204.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tay", 
        "givenName": "Kwang Hong", 
        "id": "sg:person.01204255216.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204255216.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersey", 
        "givenName": "Peter", 
        "id": "sg:person.01073667716.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xu Dong", 
        "id": "sg:person.01210116316.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1210655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022703258", 
          "https://doi.org/10.1038/sj.onc.1210655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/5517", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010598958", 
          "https://doi.org/10.1038/5517"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049638392", 
          "https://doi.org/10.1038/sj.onc.1207830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35101078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021222128", 
          "https://doi.org/10.1038/35101078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng1097-141", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040087526", 
          "https://doi.org/10.1038/ng1097-141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2637", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032375076", 
          "https://doi.org/10.1038/nrd2637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840626", 
          "https://doi.org/10.1038/sj.onc.1209597"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10495-006-0283-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032980663", 
          "https://doi.org/10.1007/s10495-006-0283-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-006-0207-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045207664", 
          "https://doi.org/10.1007/s00280-006-0207-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-12-14", 
    "datePublishedReg": "2009-12-14", 
    "description": "BackgroundPast studies have shown that sensitivity of melanoma cells to TRAIL-induced apoptosis is largely correlated with the expression levels of TRAIL death receptors on the cell surface. However, fresh melanoma isolates and melanoma tissue sections express generally low levels of death receptors for TRAIL. The clinical potential of TRAIL in the treatment of melanoma may therefore be limited unless given with agents that increase the cell surface expression of TRAIL death receptors. 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analogue that inhibits glycolysis and glycosylation and blocks cell growth. It has been in clinical evaluation for its potential use as an anticancer agent. In this study, we have examined whether 2-DG and TRAIL interact to enhance their cytotoxicity towards melanoma cells.Results2-DG did not kill melanoma cells, but enhanced TRAIL-induced apoptosis in cultured melanoma cells and fresh melanoma isolates. This was associated with increased activation of the caspase cascade and mitochondrial apoptotic pathway, and was blocked by inhibition of TRAIL-R2, and to a lesser extent, inhibition of TRAIL-R1. Treatment with 2-DG up-regulated TRAIL death receptors, in particular, TRAIL-R2, on the melanoma cell surface. Up-regulation of TRAIL-R2 was due to increased transcription that was not dependent on the transcription factors, p53 and CHOP. Instead, the IRE1\u03b1 and ATF6 pathways of the unfolded protein response that were activated by 2-DG appeared to be involved. Moreover, XBP-1, which is known to be transcriptionally regulated by ATF6 and functionally activated by IRE1\u03b1, was found to play an important role in 2-DG-mediated transcriptional up-regulation of TRAIL-R2 in melanoma cells.ConclusionThese results indicate that 2-DG sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-2 via the ATF6/IRE1\u03b1/XBP-1 axis of the unfolded protein response. They suggest that 2-DG is a promising agent to increase the therapeutic response to TRAIL in melanoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1476-4598-8-122", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031030", 
        "issn": [
          "1476-4598"
        ], 
        "name": "Molecular Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "TRAIL death receptors", 
      "TRAIL-R2", 
      "human melanoma cells", 
      "melanoma cells", 
      "death receptors", 
      "fresh melanoma isolates", 
      "treatment of melanoma", 
      "synthetic glucose analog", 
      "unfolded protein response", 
      "IRE1\u03b1/XBP", 
      "melanoma tissue sections", 
      "cultured melanoma cells", 
      "melanoma cell surface", 
      "TRAIL-induced apoptosis", 
      "clinical evaluation", 
      "therapeutic response", 
      "cell surface expression", 
      "protein response", 
      "ConclusionThese results", 
      "block cell growth", 
      "promising agent", 
      "TRAIL-R1", 
      "clinical potential", 
      "cell surface", 
      "ATF6 pathway", 
      "receptors", 
      "surface expression", 
      "tissue sections", 
      "mitochondrial apoptotic pathway", 
      "expression levels", 
      "glucose analog", 
      "XBP-1", 
      "anticancer agents", 
      "apoptosis", 
      "melanoma", 
      "Trails 2", 
      "apoptotic pathway", 
      "cell growth", 
      "cells", 
      "treatment", 
      "inhibition", 
      "low levels", 
      "IRE1\u03b1", 
      "agents", 
      "caspase cascade", 
      "lesser extent", 
      "response", 
      "isolates", 
      "transcription factors", 
      "pathway", 
      "D-glucose", 
      "important role", 
      "potential use", 
      "CHOP", 
      "p53", 
      "levels", 
      "study", 
      "cytotoxicity", 
      "activation", 
      "trails", 
      "ATF6", 
      "glycolysis", 
      "expression", 
      "XBP", 
      "factors", 
      "evaluation", 
      "cascade", 
      "role", 
      "regulation", 
      "sensitivity", 
      "transcription", 
      "use", 
      "axis", 
      "analogues", 
      "extent", 
      "glycosylation", 
      "potential", 
      "sections", 
      "results", 
      "growth", 
      "surface"
    ], 
    "name": "2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2", 
    "pagination": "122", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037487578"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1476-4598-8-122"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20003459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1476-4598-8-122", 
      "https://app.dimensions.ai/details/publication/pub.1037487578"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_485.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1476-4598-8-122"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1476-4598-8-122'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1476-4598-8-122'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1476-4598-8-122'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1476-4598-8-122'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      21 PREDICATES      128 URIs      111 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1476-4598-8-122 schema:about N05d65caff70a42f19319a3255ed8d7fd
2 N15d4a5108e334b709ff2d329e13e955e
3 N1d66e65e72604a149ac9623e5a181199
4 N22c9540c484c4119a6de9ab108e985b5
5 N33dc7bcea10e4044a6eed6a6c14d4744
6 N3940a3f97e7044cdb8e11458711d593e
7 N398ed3f997114a039999c6a05d60ffd6
8 N57386141b9cd4f008e04737c88a3820e
9 N58060df95fd2463eb05aa49dd5aac198
10 N91267ed279b240249b849df745de0d82
11 Nc98088636d294a1198cb94605a57feb4
12 Nde4c8e359daa49ddb445f2af65fdfb8e
13 Nefd48f55fe7d41f0896aeb2bca353f5e
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N6dfea01aab414b52b1ed515eb62d68eb
17 schema:citation sg:pub.10.1007/s00280-006-0207-8
18 sg:pub.10.1007/s10495-006-0283-6
19 sg:pub.10.1038/35101078
20 sg:pub.10.1038/5517
21 sg:pub.10.1038/ng1097-141
22 sg:pub.10.1038/nrd2637
23 sg:pub.10.1038/sj.onc.1207830
24 sg:pub.10.1038/sj.onc.1209597
25 sg:pub.10.1038/sj.onc.1210655
26 schema:datePublished 2009-12-14
27 schema:datePublishedReg 2009-12-14
28 schema:description BackgroundPast studies have shown that sensitivity of melanoma cells to TRAIL-induced apoptosis is largely correlated with the expression levels of TRAIL death receptors on the cell surface. However, fresh melanoma isolates and melanoma tissue sections express generally low levels of death receptors for TRAIL. The clinical potential of TRAIL in the treatment of melanoma may therefore be limited unless given with agents that increase the cell surface expression of TRAIL death receptors. 2-Deoxy-D-glucose (2-DG) is a synthetic glucose analogue that inhibits glycolysis and glycosylation and blocks cell growth. It has been in clinical evaluation for its potential use as an anticancer agent. In this study, we have examined whether 2-DG and TRAIL interact to enhance their cytotoxicity towards melanoma cells.Results2-DG did not kill melanoma cells, but enhanced TRAIL-induced apoptosis in cultured melanoma cells and fresh melanoma isolates. This was associated with increased activation of the caspase cascade and mitochondrial apoptotic pathway, and was blocked by inhibition of TRAIL-R2, and to a lesser extent, inhibition of TRAIL-R1. Treatment with 2-DG up-regulated TRAIL death receptors, in particular, TRAIL-R2, on the melanoma cell surface. Up-regulation of TRAIL-R2 was due to increased transcription that was not dependent on the transcription factors, p53 and CHOP. Instead, the IRE1α and ATF6 pathways of the unfolded protein response that were activated by 2-DG appeared to be involved. Moreover, XBP-1, which is known to be transcriptionally regulated by ATF6 and functionally activated by IRE1α, was found to play an important role in 2-DG-mediated transcriptional up-regulation of TRAIL-R2 in melanoma cells.ConclusionThese results indicate that 2-DG sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-2 via the ATF6/IRE1α/XBP-1 axis of the unfolded protein response. They suggest that 2-DG is a promising agent to increase the therapeutic response to TRAIL in melanoma.
29 schema:genre article
30 schema:isAccessibleForFree true
31 schema:isPartOf N49424c13233c4635951e71d85b18909d
32 Ncee7071b94754d4d9a8b3b38684f462d
33 sg:journal.1031030
34 schema:keywords ATF6
35 ATF6 pathway
36 CHOP
37 ConclusionThese results
38 D-glucose
39 IRE1α
40 IRE1α/XBP
41 TRAIL death receptors
42 TRAIL-R1
43 TRAIL-R2
44 TRAIL-induced apoptosis
45 Trails 2
46 XBP
47 XBP-1
48 activation
49 agents
50 analogues
51 anticancer agents
52 apoptosis
53 apoptotic pathway
54 axis
55 block cell growth
56 cascade
57 caspase cascade
58 cell growth
59 cell surface
60 cell surface expression
61 cells
62 clinical evaluation
63 clinical potential
64 cultured melanoma cells
65 cytotoxicity
66 death receptors
67 evaluation
68 expression
69 expression levels
70 extent
71 factors
72 fresh melanoma isolates
73 glucose analog
74 glycolysis
75 glycosylation
76 growth
77 human melanoma cells
78 important role
79 inhibition
80 isolates
81 lesser extent
82 levels
83 low levels
84 melanoma
85 melanoma cell surface
86 melanoma cells
87 melanoma tissue sections
88 mitochondrial apoptotic pathway
89 p53
90 pathway
91 potential
92 potential use
93 promising agent
94 protein response
95 receptors
96 regulation
97 response
98 results
99 role
100 sections
101 sensitivity
102 study
103 surface
104 surface expression
105 synthetic glucose analog
106 therapeutic response
107 tissue sections
108 trails
109 transcription
110 transcription factors
111 treatment
112 treatment of melanoma
113 unfolded protein response
114 use
115 schema:name 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2
116 schema:pagination 122
117 schema:productId N343f46e176b947f7a6b0b76c1699274f
118 Ne56b3e255e4f45f0b6c3ebb447c8431c
119 Nf288837d094043ee9a6fdf0144b3b738
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037487578
121 https://doi.org/10.1186/1476-4598-8-122
122 schema:sdDatePublished 2022-11-24T20:54
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Na4326557722e401b9c737b9185a90a0e
125 schema:url https://doi.org/10.1186/1476-4598-8-122
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N05d65caff70a42f19319a3255ed8d7fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Melanoma
131 rdf:type schema:DefinedTerm
132 N07b92bcc610b4ae492928d14d32ebe5a rdf:first sg:person.01210116316.18
133 rdf:rest rdf:nil
134 N15d4a5108e334b709ff2d329e13e955e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Cell Line, Tumor
136 rdf:type schema:DefinedTerm
137 N1998abd1e00a41338186f677dd0c3b8a rdf:first sg:person.01073667716.42
138 rdf:rest N07b92bcc610b4ae492928d14d32ebe5a
139 N1d66e65e72604a149ac9623e5a181199 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Regulatory Factor X Transcription Factors
141 rdf:type schema:DefinedTerm
142 N22c9540c484c4119a6de9ab108e985b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Apoptosis
144 rdf:type schema:DefinedTerm
145 N33dc7bcea10e4044a6eed6a6c14d4744 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name TNF-Related Apoptosis-Inducing Ligand
147 rdf:type schema:DefinedTerm
148 N343f46e176b947f7a6b0b76c1699274f schema:name doi
149 schema:value 10.1186/1476-4598-8-122
150 rdf:type schema:PropertyValue
151 N3940a3f97e7044cdb8e11458711d593e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 N398ed3f997114a039999c6a05d60ffd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Receptors, TNF-Related Apoptosis-Inducing Ligand
156 rdf:type schema:DefinedTerm
157 N49424c13233c4635951e71d85b18909d schema:volumeNumber 8
158 rdf:type schema:PublicationVolume
159 N57386141b9cd4f008e04737c88a3820e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Glycosylation
161 rdf:type schema:DefinedTerm
162 N58060df95fd2463eb05aa49dd5aac198 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Up-Regulation
164 rdf:type schema:DefinedTerm
165 N5e83a740e44344dfa95fd87b9883e83c rdf:first sg:person.01007554442.39
166 rdf:rest Nfe59dcc728174d87b7f85cd10912aca0
167 N6dfea01aab414b52b1ed515eb62d68eb rdf:first sg:person.01212142420.00
168 rdf:rest N79eabe2492234e948779d95ca40996a8
169 N79eabe2492234e948779d95ca40996a8 rdf:first sg:person.0617201523.26
170 rdf:rest N5e83a740e44344dfa95fd87b9883e83c
171 N91267ed279b240249b849df745de0d82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Deoxyglucose
173 rdf:type schema:DefinedTerm
174 Na4326557722e401b9c737b9185a90a0e schema:name Springer Nature - SN SciGraph project
175 rdf:type schema:Organization
176 Nc98088636d294a1198cb94605a57feb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name DNA-Binding Proteins
178 rdf:type schema:DefinedTerm
179 Ncee7071b94754d4d9a8b3b38684f462d schema:issueNumber 1
180 rdf:type schema:PublicationIssue
181 Ndcf2b748e3264612b5b222a48812d0ed rdf:first sg:person.01032164214.33
182 rdf:rest Neef8db196c1e49a18c9008c747b95604
183 Nde4c8e359daa49ddb445f2af65fdfb8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Transcription Factors
185 rdf:type schema:DefinedTerm
186 Ne56b3e255e4f45f0b6c3ebb447c8431c schema:name pubmed_id
187 schema:value 20003459
188 rdf:type schema:PropertyValue
189 Nea9294011d3241899c6678d06d20651a rdf:first sg:person.01204255216.26
190 rdf:rest N1998abd1e00a41338186f677dd0c3b8a
191 Neef8db196c1e49a18c9008c747b95604 rdf:first sg:person.0755651204.44
192 rdf:rest Nea9294011d3241899c6678d06d20651a
193 Nefd48f55fe7d41f0896aeb2bca353f5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name X-Box Binding Protein 1
195 rdf:type schema:DefinedTerm
196 Nf288837d094043ee9a6fdf0144b3b738 schema:name dimensions_id
197 schema:value pub.1037487578
198 rdf:type schema:PropertyValue
199 Nfa0d8fe3f96f4c759ac110f78d6b871c rdf:first sg:person.01136142016.09
200 rdf:rest Ndcf2b748e3264612b5b222a48812d0ed
201 Nfe59dcc728174d87b7f85cd10912aca0 rdf:first sg:person.01215144734.56
202 rdf:rest Nfa0d8fe3f96f4c759ac110f78d6b871c
203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
204 schema:name Medical and Health Sciences
205 rdf:type schema:DefinedTerm
206 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
207 schema:name Oncology and Carcinogenesis
208 rdf:type schema:DefinedTerm
209 sg:journal.1031030 schema:issn 1476-4598
210 schema:name Molecular Cancer
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01007554442.39 schema:affiliation grid-institutes:grid.413265.7
214 schema:familyName Lavis
215 schema:givenName Christopher J
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007554442.39
217 rdf:type schema:Person
218 sg:person.01032164214.33 schema:affiliation grid-institutes:grid.413265.7
219 schema:familyName Tseng
220 schema:givenName Hsin-Yi
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032164214.33
222 rdf:type schema:Person
223 sg:person.01073667716.42 schema:affiliation grid-institutes:grid.413265.7
224 schema:familyName Hersey
225 schema:givenName Peter
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
227 rdf:type schema:Person
228 sg:person.01136142016.09 schema:affiliation grid-institutes:grid.413265.7
229 schema:familyName Dong
230 schema:givenName Li
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136142016.09
232 rdf:type schema:Person
233 sg:person.01204255216.26 schema:affiliation grid-institutes:grid.413265.7
234 schema:familyName Tay
235 schema:givenName Kwang Hong
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204255216.26
237 rdf:type schema:Person
238 sg:person.01210116316.18 schema:affiliation grid-institutes:grid.413265.7
239 schema:familyName Zhang
240 schema:givenName Xu Dong
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18
242 rdf:type schema:Person
243 sg:person.01212142420.00 schema:affiliation grid-institutes:grid.252957.e
244 schema:familyName Liu
245 schema:givenName Hao
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212142420.00
247 rdf:type schema:Person
248 sg:person.01215144734.56 schema:affiliation grid-institutes:grid.413265.7
249 schema:familyName Croft
250 schema:givenName Amanda
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215144734.56
252 rdf:type schema:Person
253 sg:person.0617201523.26 schema:affiliation grid-institutes:grid.413265.7
254 schema:familyName Jiang
255 schema:givenName Chen Chen
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617201523.26
257 rdf:type schema:Person
258 sg:person.0755651204.44 schema:affiliation grid-institutes:grid.413265.7
259 schema:familyName Yang
260 schema:givenName Fan
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755651204.44
262 rdf:type schema:Person
263 sg:pub.10.1007/s00280-006-0207-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045207664
264 https://doi.org/10.1007/s00280-006-0207-8
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s10495-006-0283-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032980663
267 https://doi.org/10.1007/s10495-006-0283-6
268 rdf:type schema:CreativeWork
269 sg:pub.10.1038/35101078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021222128
270 https://doi.org/10.1038/35101078
271 rdf:type schema:CreativeWork
272 sg:pub.10.1038/5517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010598958
273 https://doi.org/10.1038/5517
274 rdf:type schema:CreativeWork
275 sg:pub.10.1038/ng1097-141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040087526
276 https://doi.org/10.1038/ng1097-141
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/nrd2637 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032375076
279 https://doi.org/10.1038/nrd2637
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/sj.onc.1207830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049638392
282 https://doi.org/10.1038/sj.onc.1207830
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/sj.onc.1209597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840626
285 https://doi.org/10.1038/sj.onc.1209597
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/sj.onc.1210655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022703258
288 https://doi.org/10.1038/sj.onc.1210655
289 rdf:type schema:CreativeWork
290 grid-institutes:grid.252957.e schema:alternateName Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, PR China
291 schema:name Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, PR China
292 Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia
293 rdf:type schema:Organization
294 grid-institutes:grid.413265.7 schema:alternateName Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia
295 schema:name Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Room 443, NSW, Australia
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...